 Connection
Robert Weinstein to Alendronate
This is a "connection" page, showing publications Robert Weinstein has written about Alendronate.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.019 |
|
|
|
-
Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5?mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010 Oct; 25(10):2239-50.
Score: 0.368
-
Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med. 2009 Jan 01; 360(1):53-62.
Score: 0.326
-
Weinstein RS, Chen JR, Powers CC, Stewart SA, Landes RD, Bellido T, Jilka RL, Parfitt AM, Manolagas SC. Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids. J Clin Invest. 2002 Apr; 109(8):1041-8.
Score: 0.204
-
Weinstein RS. Glucocorticoid-induced osteonecrosis. Endocrine. 2012 Apr; 41(2):183-90.
Score: 0.100
-
Plotkin LI, Lezcano V, Thostenson J, Weinstein RS, Manolagas SC, Bellido T. Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res. 2008 Nov; 23(11):1712-21.
Score: 0.020
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|